Results 131 to 140 of about 1,115 (163)

Avatrombopag

Reactions Weekly
  +13 more sources

An evaluation of avatrombopag for the treatment of thrombocytopenia

Expert Opinion on Pharmacotherapy, 2020
Introduction: The thrombopoietin receptor agonists (TPO-RAs) are a class of drugs that have been FDA-approved for immune thrombocytopenia (ITP), periprocedural thrombocytopenia in patients with chronic liver disease (CLD), aplastic anemia, and thrombocytopenia associated with antiviral treatment of hepatitis C.
Zain Mohammad, Virk, David J, Kuter, Hanny, Al-Samkari   +2 more
openaire   +2 more sources

Avatrombopag: First Global Approval

Drugs, 2018
Avatrombopag (Doptelet®) is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders. In May 2018 avatrombopag received its first global approval, in the USA, for use in the treatment of thrombocytopenia in adult patients with chronic liver ...
openaire   +2 more sources

Avatrombopag: Beyond efficacy

Blood
Abstract INTRODUCTION Thrombopoietin Agonists (TPO-AR) are the treatment of choice in 2nd line in ITP. There are different agonists that act at different levels and with different modes of administration.
Manuel Rodriguez Lopez, Elena Yaiza Romero Ventisa, Antia Amoedo Bastos, Gala Cabirta Touzon, Raquel Ocampo Martinez, Carmen Albo Lopez   +5 more
openaire   +1 more source

Avatrombopag

Reactions Weekly, 2023
openaire   +1 more source

Avatrombopag (Doptelet)

Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire   +1 more source

A second chance for avatrombopag in chemotherapy‐induced thrombocytopenia

British Journal of Haematology
Chemotherapy‐induced thrombocytopenia (CIT) remains a common complication of cancer therapy with no approved available treatments in most of the world. Although a prior clinical trial of avatrombopag for CIT did not meet its primary end‐point, a report from Galamaga and colleagues raises prospects for a second chance for avatrombopag in CIT ...
Hanny Al‐Samkari, Donald C. Moore
openaire   +2 more sources

The Structure, Function, and Clinical Use of the Thrombopoietin Receptor Agonist Avatrombopag

Blood Reviews, 2022
David John Kuter
exaly  

Adults With Immune Thrombocytopenia Who Switched to Avatrombopag Following Prior Treatment With Eltrombopag or Romiplostim: A Multicentre US Study

British Journal of Haematology, 2022
Hanny Al-Samkari, Debbie C. Jiang, Adam Cuker   +2 more
exaly  

Avatrombopag for Adult Chronic Primary Immune Thrombocytopenia: A Randomized Phase 3 Trial in China

Research and Practice in Thrombosis and Haemostasis, 2023
Jianmin Luo, Xu Ye
exaly